Compare HLF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | EVO |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 994.5M |
| IPO Year | 2004 | N/A |
| Metric | HLF | EVO |
|---|---|---|
| Price | $12.98 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $18.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.6M | 30.3K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $5,037,500,000.00 | N/A |
| Revenue This Year | $4.97 | $1.37 |
| Revenue Next Year | $3.80 | $10.05 |
| P/E Ratio | $22.79 | ★ N/A |
| Revenue Growth | ★ 0.89 | N/A |
| 52 Week Low | $7.56 | $2.31 |
| 52 Week High | $20.40 | $4.42 |
| Indicator | HLF | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 55.62 |
| Support Level | $12.55 | $2.60 |
| Resistance Level | $13.09 | $3.30 |
| Average True Range (ATR) | 0.57 | 0.06 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 82.45 | 83.78 |
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.